Diagnostics of inflammatory bowel disease.

The diagnosis of inflammatory bowel disease (IBD) with its 2 main subforms, Crohn's disease and ulcerative colitis, is based on clinical, endoscopic, radiologic, and histologic criteria. This paradigm remains unchanged despite the advent of new molecular technologies for the examination of serum proteins and genetic sequences, respectively. The main innovations in diagnostic technologies include the development of more sophisticated endoscopic and noninvasive imaging techniques with the aim of improving the identification of complications, in particular malignant diseases associated with IBD. The future will see further progress in the identification of genetic susceptibility factors and of protein biomarkers and their use to describe the molecular epidemiology of IBD. It can be expected that future diagnostic algorithms will include molecular parameters to detect early disease or guide therapies by predicting the individual course of disease.

[1]  M. G. Brizi,et al.  Crohn disease: magnetic resonance enteroclysis , 2004, Abdominal Imaging.

[2]  R. Jonsson,et al.  Effects of Human Calprotectin (L1) on In Vitro Immunoglobulin Synthesis , 1994, Scandinavian journal of immunology.

[3]  A. Peters,et al.  111Indium autologous granulocytes in the detection of inflammatory bowel disease. , 1985, Gut.

[4]  J. H. Baron,et al.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. , 1962, Lancet.

[5]  Jonathan Braun,et al.  Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. , 2002, Gastroenterology.

[6]  J. Colombel,et al.  Relevance of serologic studies in inflammatory bowel disease , 2004, Current gastroenterology reports.

[7]  G. Casazza,et al.  Role of US in detection of Crohn disease: meta-analysis. , 2005, Radiology.

[8]  J. Talwalkar,et al.  Primary sclerosing cholangitis. , 2002, Seminars in gastrointestinal disease.

[9]  L. Ryner,et al.  A Prospective Comparison Study of MRI versus Small Bowel Follow-Through in Recurrent Crohn's Disease , 2005, The American Journal of Gastroenterology.

[10]  R. Sjödahl,et al.  Passage of molecules through the wall of the gastrointestinal tract. I. A simple experimental model. , 1978, Scandinavian journal of gastroenterology.

[11]  R. Hutchinson,et al.  Pathogenesis of gall stones in Crohn's disease: an alternative explanation. , 1994, Gut.

[12]  Dennis Christie,et al.  Serum Immune Responses Predict Rapid Disease Progression among Children with Crohn's Disease: Immune Responses Predict Disease Progression , 2006, The American Journal of Gastroenterology.

[13]  W. Thompson,et al.  Lymphocytic colitis , 1993, Digestive Diseases and Sciences.

[14]  Judy H Cho,et al.  Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis , 2007, Nature Genetics.

[15]  C. Nahmias,et al.  Positron Emission Tomography in the Investigation of Pediatric Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[16]  L. Havelec,et al.  Collagenous colitis: a study of the distribution of morphological abnormalities and their histological detection. , 1999, Human pathology.

[17]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[18]  W. Lamorte,et al.  Anti — Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis , 2007, Journal of Gastrointestinal Surgery.

[19]  S. Targan,et al.  Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease. , 2006, Advances in experimental medicine and biology.

[20]  J. Hampe,et al.  Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease , 1999, The Lancet.

[21]  B. Thjódleifsson,et al.  A simple method for assessing intestinal inflammation in Crohn's disease , 2000, Gut.

[22]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[23]  J. Rotter,et al.  Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. , 1986, Annals of internal medicine.

[24]  C. Yeh,et al.  Comparative proteomic studies on the pathogenesis of human ulcerative colitis , 2006, Proteomics.

[25]  M. Scheurlen,et al.  [Localization and extent of Crohn disease at initial diagnosis]. , 1987, Medizinische Klinik.

[26]  Amy K Hara,et al.  A Meta-Analysis of the Yield of Capsule Endoscopy Compared to Other Diagnostic Modalities in Patients with Non-Stricturing Small Bowel Crohn's Disease , 2006, The American Journal of Gastroenterology.

[27]  Alastair Forbes,et al.  Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility , 2007, Nature Genetics.

[28]  S. Schreiber,et al.  P178 Early Crohn's Disease Shows High Levels of Remission to Therapy with Adalimumab: Sub-Analysis of Charm , 2007 .

[29]  I. Orengo,et al.  Squamous cell carcinoma in solid-organ transplantation. , 2002, Dermatology online journal.

[30]  D. Rubin,et al.  Surveillance for cancer and dysplasia in inflammatory bowel disease. , 2006, Gastroenterology clinics of North America.

[31]  Judy H. Cho,et al.  [Letters to Nature] , 1975, Nature.

[32]  S. Meuwissen,et al.  Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. , 1978, Annals of the rheumatic diseases.

[33]  T. Bayless,et al.  Lymphocytic ("microscopic") colitis: a comparative histopathologic study with particular reference to collagenous colitis. , 1989, Human pathology.

[34]  C. O'Morain,et al.  The prevalence of genetic and serologic markers in an unselected European population‐based cohort of IBD patients , 2007, Inflammatory bowel diseases.

[35]  I. Innerfield,et al.  ANTITHROMBIN ACTIVITY IN HOMOCYSTINURIA , 1975, The Lancet.

[36]  M. De Vos,et al.  Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. , 2000, The Journal of rheumatology.

[37]  S S Cross,et al.  Detecting diminutive colorectal lesions at colonoscopy: a randomised controlled trial of pan-colonic versus targeted chromoscopy , 2004, Gut.

[38]  S. Targan,et al.  Anti‐flagellin (CBir1) phenotypic and genetic Crohn's disease associations , 2007, Inflammatory bowel diseases.

[39]  Mario Albrecht,et al.  Genetics of Crohn disease, an archetypal inflammatory barrier disease , 2005, Nature Reviews Genetics.

[40]  Athos Bousvaros,et al.  The Crohn’s and Colitis Foundation of America , 2018, The Grants Register 2019.

[41]  W. Tremaine.  Collagenous colitis and lymphocytic colitis. , 2000, Journal of Clinical Gastroenterology.

[42]  O. Schober,et al.  High Diagnostic Value of 18F–FDG–PET in Pediatric Patients with Chronic Inflammatory Bowel Disease , 2006, Annals of the New York Academy of Sciences.

[43]  Thomas Lengauer,et al.  A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 , 2007, Nature Genetics.

[44]  W. Su,et al.  Pyoderma gangrenosum: classification and management. , 1996, Journal of the American Academy of Dermatology.

[45]  H. Kirchmann,et al.  Diagnostic Significance of Epithelioid Granulomas in Crohn's Disease in Children , 1990, Journal of Pediatric Gastroenterology and Nutrition - JPGN.

[46]  R. Hultcrantz,et al.  Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. , 1994, Gut.

[47]  Philip Rosenstiel,et al.  Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci , 2007, Proceedings of the National Academy of Sciences.

[48]  S. Targan,et al.  Bacterial flagellin is a dominant antigen in Crohn disease , 2004 .

[49]  Y. Fujiwara,et al.  Evaluation of Deep Small Bowel Involvement by Double-Balloon Enteroscopy in Crohn's Disease , 2006, The American Journal of Gastroenterology.

[50]  Shin-ei Kudo,et al.  Flat and depressed lesions of the colorectum. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  J. Mallet,et al.  Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. , 2006, Gastroenterology.

[52]  J. Hampe,et al.  Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. , 2002, Pharmacogenetics.

[53]  W. Mow,et al.  Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. , 2004, Gastroenterology.

[54]  E. Lingaas,et al.  Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin , 1990, The Lancet.

[55]  J. Kirsner,et al.  The epidemiologic and demographic characteristics of inflammatory bowel disease: an analysis of a computerized file of 1400 patients. , 1971, Journal of chronic diseases.

[56]  J. Goldberg,et al.  Granulomas do not affect postoperative recurrence rates in Crohn's disease. , 1982, Gastroenterology.

[57]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[58]  N. Harpaz,et al.  Diagnosis of colitis: making the initial diagnosis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[59]  Phillip Fleshner,et al.  Serologic Responses in Indeterminate Colitis Patients Before Ileal Pouch-Anal Anastomosis May Determine Those at Risk for Continuous Pouch Inflammation , 2005, Diseases of the colon and rectum.

[60]  A. Darzi,et al.  Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy , 2007, The American Journal of Gastroenterology.

[61]  S. Targan,et al.  Identification of a novel bacterial sequence associated with Crohn's disease. , 2000, Gastroenterology.

[62]  Thomas Lengauer,et al.  Genetic variation in DLG5 is associated with inflammatory bowel disease , 2004, Nature Genetics.

[63]  B. Cesana,et al.  Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening. , 1996, The American journal of gastroenterology.

[64]  U. Schmiedl,et al.  Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging. , 1989, AJR. American journal of roentgenology.

[65]  M. Reiser,et al.  [Computed tomography in the diagnosis of inflammatory bowel disease -- methodology of MSCT and clinical results]. , 2003, Der Radiologe.

[66]  R. Kiesslich,et al.  Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. , 2007, Gastroenterology.

[67]  J. Hugot,et al.  Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: prevalence and diagnostic value. , 1997, Journal of pediatric gastroenterology and nutrition.

[68]  W. Hannan,et al.  Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. , 1994, Gastroenterology.

[69]  Ching-Hon Pui,et al.  Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.

[70]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[71]  P. Rutgeerts,et al.  The ideal management of Crohn's disease: Top down versus step up strategies, a randomized controlled trial , 2006 .

[72]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[73]  S. Targan,et al.  Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis , 2006, Gut.

[74]  D. J. King,et al.  Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia , 1999, British journal of haematology.

[75]  S. Yui,et al.  Growth‐inhibitory and apoptosis‐inducing activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: regulation by metal ions , 1997, Journal of leukocyte biology.

[76]  Chi-Yang Chang,et al.  A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia , 2007, Gut.

[77]  The Clinical Impact of Thiopurine Methyltransferase Polymorphisms on Thiopurine Treatment , 2004, Nucleosides, nucleotides & nucleic acids.

[78]  R. Modigliani,et al.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. , 1990, Gastroenterology.

[79]  Y. Sano,et al.  Chromoendoscopy using indigo carmine dye spraying with magnifying observation is the most reliable method for differential diagnosis between non-neoplastic and neoplastic colorectal lesions: a prospective study. , 2004, Endoscopy.

[80]  G. D'Haens,et al.  Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. , 1999, Gastroenterology.

[81]  T. Thomas,et al.  Meta‐analysis: cancer risk of low‐grade dysplasia in chronic ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[82]  P. Rutgeerts,et al.  Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? , 2007, Gut.

[83]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[84]  J. V. van Engelshoven,et al.  Preoperative MR imaging of anal fistulas: Does it really help the surgeon? , 2001, Radiology.

[85]  S. Friedman.  Cancer in Crohn's disease. , 2006, Gastroenterology clinics of North America.

[86]  Simon Heath,et al.  Novel Crohn Disease Locus Identified by Genome-Wide Association Maps to a Gene Desert on 5p13.1 and Modulates Expression of PTGER4 , 2007, PLoS genetics.

[87]  Ami,et al.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.

[88]  S. Brant,et al.  Antibodies to Saccharomyces cerevisiae in Crohn's disease: Higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease , 2007, Inflammatory bowel diseases.

[89]  S. Hanauer.  Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". , 2007, Reviews in gastroenterological disorders.

[90]  J. Belaiche,et al.  NOD2/CARD15 does not influence response to infliximab in Crohn's disease. , 2002, Gastroenterology.

[91]  B. Moum,et al.  Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). , 2002, The Journal of rheumatology.

[92]  S. Targan,et al.  NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. , 2007, Gastroenterology.

[93]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[94]  Syed G. Shah,et al.  Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial. , 2002, Gastrointestinal endoscopy.

[95]  S. Gallus,et al.  Oral contrast enhanced bowel ultrasonography in the assessment of small intestine Crohn’s disease. A prospective comparison with conventional ultrasound, x ray studies, and ileocolonoscopy , 2004, Gut.

[96]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[97]  I. Bjarnason,et al.  The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. , 1991, Gastroenterology.

[98]  V. Ho,et al.  Cutaneous manifestations of gastrointestinal disorders. Part I. , 1992, Journal of the American Academy of Dermatology.

[99]  W. Domschke,et al.  Fluorescence Endoscopy Using a Fluorescein-Labeled Monoclonal Antibody Against Carcinoembryonic Antigen in Patients with Colorectal Carcinoma and Adenoma , 2002, Endoscopy.

[100]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[101]  P. Rosenstiel,et al.  The Met-196 → Arg Variation of Human Tumor Necrosis Factor Receptor 2 (TNFR2) Affects TNF-α-induced Apoptosis by Impaired NF-κB Signaling and Target Gene Expression* , 2005, Journal of Biological Chemistry.

[102]  S. Rickes,et al.  Non-invasive evaluation of activity in inflammatory bowel disease by power Doppler sonography. , 2002, Zeitschrift fur Gastroenterologie.

[103]  A. Polglase,et al.  Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. , 2004, Gastroenterology.

[104]  C. Bernstein.  Neoplasia in inflammatory bowel disease: Surveillance and management strategies , 2006, Current gastroenterology reports.

[105]  O. B. Schaffalitzky de Muckadell,et al.  Intestinal permeability of 51Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn's disease and their healthy relatives. , 1989, Scandinavian journal of gastroenterology.

[106]  S. Fisher,et al.  Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations , 2001, The Lancet.

[107]  A. Bousvaros,et al.  Serologic Testing with ANCA, ASCA, and Anti-OmpC in Children and Young Adults with Crohn's Disease and Ulcerative Colitis: Diagnostic Value and Correlation with Disease Phenotype , 2004, The American Journal of Gastroenterology.

[108]  D. Blondin,et al.  Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. , 2006, European journal of radiology.

[109]  J Y Mary,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.

[110]  G. Veres,et al.  Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients , 2007, Inflammatory bowel diseases.

[111]  R. Franchis,et al.  Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[112]  H. Lehrach,et al.  Analysis of NOD2-mediated Proteome Response to Muramyl Dipeptide in HEK293 Cells* , 2006, Journal of Biological Chemistry.

[113]  E. Toth,et al.  Role of chromoendoscopy in colon cancer surveillance in inflammatory bowel disease , 2007, Inflammatory bowel diseases.

[114]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[115]  G. May,et al.  Is small intestinal permeability really increased in relatives of patients with Crohn's disease? , 1993, Gastroenterology.

[116]  R. M. Beattie,et al.  Sonographic evaluation of inflammatory bowel disease: a prospective, blinded, comparative study , 2006, Pediatric Radiology.

[117]  W. Sandborn,et al.  Lymphocytic Colitis: clinical features, treatment, and outcomes , 2002, American Journal of Gastroenterology.

[118]  H. Freeman.  Natural History and Clinical Behavior of Crohn's Disease Extending Beyond Two Decades , 2003, Journal of clinical gastroenterology.

[119]  L. Greco,et al.  Effects of Disease Activity on Anti–Saccharomyces cerevisiae Antibodies: Implications for Diagnosis and Follow-up of Children with Crohn's Disease , 2004, Inflammatory bowel diseases.

[120]  A. Forbes,et al.  Microscopic colitis: the tip of the iceberg? , 2002, European journal of gastroenterology & hepatology.

[121]  A. Rieber,et al.  COST-EFFECTIVENESS OF MAGNETIC RESONANCE IMAGING AND ENTEROCLYSIS IN THE DIAGNOSTIC IMAGING OF CROHN'S DISEASE , 2002, International Journal of Technology Assessment in Health Care.

[122]  J. Rhodes,et al.  Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. , 2006, The Cochrane database of systematic reviews.

[123]  P. Sohnle,et al.  Resistance of zinc-supplemented Candida albicans cells to the growth inhibitory effect of calprotectin. , 1995, The Journal of infectious diseases.

[124]  P. Munkholm.  Crohn's disease--occurrence, course and prognosis. An epidemiologic cohort-study. , 1997, Danish medical bulletin.

[125]  R. Baldassano,et al.  Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. , 2000, Journal of clinical gastroenterology.

[126]  B. Unsal,et al.  The prevalence of ocular involvement in patients with inflammatory bowel disease , 2007, International Journal of Colorectal Disease.

[127]  A. Røseth,et al.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. , 1992, Scandinavian journal of gastroenterology.

[128]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[129]  S. Danese,et al.  Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens , 2007, The American Journal of Gastroenterology.

[130]  A. Darzi,et al.  Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease , 2006, The American Journal of Gastroenterology.

[131]  H. McLeod,et al.  Thiopurine methyltransferase alleles in British and Ghanaian populations. , 1999, Human molecular genetics.

[132]  M. Lebwohl,et al.  Cutaneous manifestations of inflammatory bowel disease. , 1998, Inflammatory bowel diseases.

[133]  I. Gotsman,et al.  Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. , 2004, The Israel Medical Association journal : IMAJ.

[134]  E. Marshall.  Preventing Toxicity With a Gene Test , 2003, Science.

[135]  L. Philipsen,et al.  Ulcerative Colitis Response Profiles in Crohn's Disease and Mucosa Reveals Distinctive Immune Proteomic Analysis of the Inflamed Intestinal , 2007 .

[136]  P. Geurts,et al.  Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. , 2007, Biochemical pharmacology.

[137]  A. Zinsmeister,et al.  A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. , 2001, Gastroenterology.

[138]  Rajiva Gupta,et al.  Anti-Saccharomyces cerevisiae Antibody Does Not Differentiate Between Crohn's Disease and Intestinal Tuberculosis , 2006, Digestive Diseases and Sciences.

[139]  R. Odze,et al.  AMACR Immunostaining is Useful in Detecting Dysplastic Epithelium in Barrett's Esophagus, Ulcerative Colitis, and Crohn's Disease , 2006, The American journal of surgical pathology.

[140]  S. Mascheretti,et al.  Genetic Testing in Crohn Disease , 2005 .

[141]  H. Lochs,et al.  Increased gastric and intestinal permeability in patients with Crohn's disease. , 1997, The American journal of gastroenterology.

[142]  R. Sjödahl,et al.  Passage of molecules through the wall of the gastrointestinal tract. Intestinal permeability to polyethyleneglycol 1 000 in patients with Crohn's disease. , 1982, Acta chirurgica Scandinavica.

[143]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[144]  D. Gaffney,et al.  Cost‐effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease , 2004, Alimentary pharmacology & therapeutics.

[145]  J. Bohr,et al.  Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Örebro, Sweden, 1993–1998 , 2004, Gut.

[146]  Michel Eichelbaum,et al.  Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. , 2004, Pharmacogenetics.

[147]  D. Jewell,et al.  Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history , 1998, Gut.

[148]  H. Worman,et al.  Anti-neutrophil antibodies in primary sclerosing cholangitis. , 2001, Best practice & research. Clinical gastroenterology.

[149]  G. Lichtenstein,et al.  Colorectal cancer in inflammatory bowel disease , 2004, Current opinion in gastroenterology.

[150]  M. Bottai,et al.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.

[151]  K. Geboes,et al.  Influence of treatment on morphological features of mucosal inflammation , 2002, Gut.

[152]  S. Targan,et al.  Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. , 2005, Gastroenterology.

[153]  Samir A. Shah,et al.  Ocular Manifestations of Inflammatory Bowel Disease , 2004, Inflammatory bowel diseases.

[154]  A. Slivka,et al.  Hepatobiliary disease in inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.

[155]  M. Yamazaki,et al.  Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium‐binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells , 1995, Journal of leukocyte biology.